⚠ Evidence warning: Clinical trials or other evidence do not support the claims that ceftolozane-tazobactam reaches cure rates of 60 to 80% in multidrug-resistant Pseudomonas and did better than meropenem against Pseudomonas in the ASPECT-NP trial, that dispersin B boosts tobramycin killing of biofilms, and that anti-Psl plus anti-PcrV antibodies help prevent Pseudomonas pneumonia. This page keeps it as a report of what people, websites or other media say.
Multidrug Resistance and Novel Therapies for Pseudomonas aeruginosa
Multidrug-resistant Pseudomonas aeruginosa is one of the most terrifying problems in modern medicine. When a patient in the intensive care unit (ICU) has a lung infection caused by a Pseudomonas strain resistant to every available antibiotic class, doctors face a choice between agents that may be ineffective or agents that are highly toxic — or both. This article explains how Pseudomonas achieves this extraordinary resistance, what last-resort antibiotics remain, and what emerging therapies offer genuine hope for the future.
Table of Contents
- MDR, XDR, and PDR: Defining the Resistance Categories
- AmpC Overexpression: The Built-In Resistance Gene
- Efflux Pumps: Pumping Antibiotics Out
- OprD Porin Loss: Closing the Door to Carbapenems
- Carbapenemases: Destroying the Last-Resort Drugs
- Ceftolozane-Tazobactam: A New Hope for MDR Strains
- Ceftazidime-Avibactam and Imipenem-Relebactam
- Colistin and Polymyxin B: The Last Resort
- Bacteriophage Therapy: Viruses That Kill Bacteria
- Anti-Quorum Sensing, CRISPR, and Future Directions
- Cefiderocol: Results of the CREDIBLE-CR Trial
- Key Research Papers
- Featured Videos
MDR, XDR, and PDR: Defining the Resistance Categories
The clinical microbiology community uses standardized definitions to classify the degree of antibiotic resistance in P. aeruginosa and other gram-negative pathogens. These definitions, established by international consensus, provide a common language for clinicians, epidemiologists, and researchers:
- Multidrug-resistant (MDR): Resistant to at least one agent in three or more of the following antibiotic categories: antipseudomonal penicillins (piperacillin-tazobactam), antipseudomonal cephalosporins (ceftazidime, cefepime), antipseudomonal carbapenems (meropenem, imipenem), fluoroquinolones (ciprofloxacin), aminoglycosides (tobramycin, amikacin), and monobactams (aztreonam). MDR Pseudomonas constitutes 15 to 30% of clinical isolates in many hospitals worldwide.
- Extensively drug-resistant (XDR): Resistant to at least one agent in all but one or two of the above categories. XDR strains leave clinicians with only one or two active drug classes — often only colistin or one novel beta-lactam combination.
- Pandrug-resistant (PDR): Resistant to all agents in all antibiotic categories. PDR Pseudomonas infections are, by definition, untreatable with approved antibiotics. They remain rare but have been documented in multiple countries and are increasing in frequency.
The World Health Organization's (WHO) 2017 Priority Pathogens List placed carbapenem-resistant P. aeruginosa in the highest "Critical" priority tier, alongside carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae. This designation drives international funding for novel antibiotic development, rapid diagnostics, and infection prevention research. ( PubMed PMID: 29276051)
The 2024 update of the World Health Organization list moved carbapenem-resistant P. aeruginosa down from "Critical" to the "High" priority tier. Its authors write that this downgrade might reflect falling resistance trends in at least one World Health Organization region, and that the move does not lessen the urgency of research into new treatments and tests for these infections. ( PubMed PMID: 40245910)
AmpC Overexpression: The Built-In Resistance Gene
Every strain of P. aeruginosa carries a chromosomal AmpC beta-lactamase gene. In most strains, this gene is kept tightly suppressed by a regulatory circuit involving the regulatory gene ampD. Exposure to certain beta-lactam antibiotics — particularly imipenem, cefoxitin, and clavulanate — can derepress AmpC expression transiently (induction). This induced AmpC hydrolyzes and inactivates penicillins and most cephalosporins. When the inducing antibiotic is removed, AmpC expression returns to baseline.
The more clinically dangerous phenomenon is stable derepression. Mutations in ampD or the related gene dacB lock AmpC into a constitutively overexpressed state — the organism permanently produces high levels of AmpC regardless of antibiotic exposure. These mutations arise spontaneously during antibiotic therapy and are strongly selected in the presence of beta-lactam antibiotics that are AmpC substrates (ceftazidime, piperacillin-tazobactam, imipenem).
The clinical consequence is dreaded: a patient treated with ceftazidime for Pseudomonas pneumonia may have a susceptible isolate on admission, but by day 5 of therapy, the culture yields an AmpC-derepressed mutant that is now resistant to ceftazidime, piperacillin-tazobactam, and even some carbapenems. This phenomenon — called emergence of resistance on therapy — occurs in 10 to 40% of serious Pseudomonas infections treated with AmpC-labile beta-lactams and is a major cause of clinical treatment failure. ( PubMed PMID: 11823954)
Efflux Pumps: Pumping Antibiotics Out
P. aeruginosa expresses multiple resistance-nodulation-division (RND) family efflux pumps that actively expel antibiotics from the bacterial cell before they can reach their intracellular targets. These pumps are among the most important resistance mechanisms in MDR Pseudomonas:
- MexAB-OprM: Constitutively expressed in all wild-type strains and contributes to the organism's inherent resistance to many antibiotics. Exports beta-lactams, fluoroquinolones, tetracyclines, chloramphenicol, and trimethoprim. Overexpression through mutations in the regulatory gene mexR increases resistance to all these classes simultaneously.
- MexXY-OprM: Inducible by ribosome-targeting antibiotics; exports aminoglycosides (tobramycin, amikacin, gentamicin) and fluoroquinolones. Overexpression is the primary mechanism of aminoglycoside resistance in many clinical isolates from people with cystic fibrosis and is driven by mutations in mexZ or through a ribosomal methylation pathway.
- MexCD-OprJ: Normally silent; overexpressed through mutations in nfxB selected by fluoroquinolone exposure. Exports fluoroquinolones and fourth-generation cephalosporins (cefepime). Overexpression of MexCD-OprJ reduces susceptibility to cefepime, an important clinical concern.
- MexEF-OprN: Overexpressed in nfxC-type mutants; exports fluoroquinolones, chloramphenicol, and trimethoprim. Upregulation of MexEF-OprN paradoxically suppresses expression of other efflux pumps through a complex regulatory network.
The simultaneous overexpression of multiple efflux pumps — driven by sequential antibiotic exposures over a patient's hospitalization history — creates MDR phenotypes from intrinsically susceptible starting organisms. ( PubMed PMID: 30500353)
OprD Porin Loss: Closing the Door to Carbapenems
OprD is a specific outer membrane porin channel through which carbapenems — particularly imipenem — enter the P. aeruginosa cell. It normally allows the uptake of basic amino acids (arginine, ornithine, histidine) and is the principal entry route for imipenem. Loss of OprD, through mutations or downregulation of the oprD gene, is the primary mechanism of imipenem resistance in clinical P. aeruginosa isolates.
OprD loss has an important pharmacological implication: imipenem resistance through OprD loss does not confer equivalent resistance to meropenem. The minimum inhibitory concentration (MIC, the lowest drug level that stops growth) for meropenem in OprD-deficient strains typically rises to intermediate or borderline resistance levels, while imipenem MICs jump to high-level resistance. This means meropenem may still be active against OprD-loss strains where imipenem has failed — but the two drugs are not equivalent for Pseudomonas treatment.
When OprD loss is combined with AmpC overexpression and MexAB-OprM upregulation, the organism achieves resistance to virtually all beta-lactam antibiotics through three complementary non-enzymatic mechanisms. This synergistic resistance — multiple mechanisms acting together — is characteristic of the most difficult clinical isolates. ( PubMed PMID: 26862399)
Carbapenemases: Destroying the Last-Resort Drugs
While the mechanisms above (OprD loss, AmpC, efflux pumps) can confer carbapenem resistance through non-enzymatic means, the most concerning resistance mechanism is acquisition of carbapenemase genes — enzymes that enzymatically hydrolyze and destroy carbapenem molecules. These genes are typically located on mobile genetic elements (plasmids, integrons, transposons) that can spread between bacteria through horizontal gene transfer.
The principal carbapenemases in P. aeruginosa include:
- Metallo-beta-lactamases (MBLs): Zinc-containing enzymes that hydrolyze virtually all beta-lactams including all carbapenems. The major MBL families are VIM (Verona Integron-encoded Metallo-beta-lactamase), IMP (Imipenem-degrading), and NDM (New Delhi Metallo-beta-lactamase). MBL-producing Pseudomonas are resistant to all beta-lactams except aztreonam and are susceptible only to the newest beta-lactam-inhibitor combinations (if the inhibitor covers MBL) or to colistin. MBL genes are widespread in Mediterranean countries, Asia, and increasingly in North America.
- GES-type enzymes: Some GES (Guiana Extended Spectrum) variants (GES-2, GES-5, GES-20) have evolved carbapenemase activity while retaining extended-spectrum beta-lactamase activity. GES carbapenemases are found in Pseudomonas isolates in South America, South Africa, and Europe.
- OXA-48-like enzymes: Primarily found in Klebsiella and Enterobacteriaceae, but increasingly reported in Pseudomonas in some geographic areas.
Detection of carbapenemase genes in a P. aeruginosa isolate triggers immediate infection control alerts: in hospital infection-control practice the patient is placed on enhanced contact precautions, contacts are screened, and in many countries regional public health authorities are notified. ( PubMed PMID: 24766095)
Ceftolozane-Tazobactam: A New Hope for MDR Strains
Ceftolozane-tazobactam was approved by the U.S. Food and Drug Administration (FDA) in 2014 for complicated urinary tract infections and intra-abdominal infections, and subsequently for hospital-acquired and ventilator-associated pneumonia. It represents a significant advance for MDR Pseudomonas specifically.
Ceftolozane is a novel cephalosporin that has several structural modifications compared to ceftazidime: an extended side chain that makes it a poor substrate for AmpC beta-lactamases, and higher intrinsic affinity for Pseudomonas penicillin-binding proteins (PBPs, the enzymes that build the cell wall; particularly PBP3) than existing cephalosporins. Tazobactam inhibits many serine beta-lactamases. The combination retains activity against many MDR Pseudomonas strains that are resistant to all other beta-lactams — including strains with AmpC derepression, MexAB-OprM overexpression, and even some with OprD loss. In the ASPECT-NP trial for hospital-acquired and ventilator-associated pneumonia, ceftolozane-tazobactam was non-inferior to meropenem for clinical cure in the overall population and numerically superior for Pseudomonas-specific infections.
In the ASPECT-NP trial of 726 patients on breathing machines with hospital-acquired or ventilator-associated pneumonia (any Gram-negative germ, not only Pseudomonas), high-dose ceftolozane-tazobactam was non-inferior to meropenem: 24.0% versus 25.3% of patients had died by day 28, and 54% versus 53% were clinically cured at the test-of-cure visit. Treatment-related side effects occurred in 11% versus 8%. ( PubMed PMID: 31563344)
For drug-resistant Pseudomonas specifically, a 2020 retrospective study from several hospitals compared 100 patients given ceftolozane-tazobactam with 100 given polymyxin- or aminoglycoside-based regimens; most were very ill (69% in intensive care, 52% with ventilator-associated pneumonia). After adjustment, ceftolozane-tazobactam was linked to more clinical cures (adjusted odds ratio 2.63) and much less acute kidney injury (adjusted odds ratio 0.08); in-hospital deaths did not differ. ( PubMed PMID: 31545346)
For MDR Pseudomonas infections in patients with no other active options, ceftolozane-tazobactam has achieved clinical cure rates of 60 to 80% in retrospective case series — remarkable results given the severity of these infections.
Critical limitation: ceftolozane-tazobactam does NOT cover MBL-producing strains (VIM, IMP, NDM). MBLs hydrolyze all cephalosporins and carbapenems, and tazobactam does not inhibit metallo-beta-lactamases. Telling AmpC- or efflux-mediated resistance apart from MBL-mediated resistance with molecular resistance testing therefore matters before ceftolozane-tazobactam is chosen.
The Infectious Diseases Society of America (IDSA) 2024 guidance on antimicrobial-resistant Gram-negative infections lists preferred and alternative treatment approaches for P. aeruginosa with "difficult-to-treat resistance" (DTR P. aeruginosa), assuming the germ has been identified and its antibiotic susceptibility results are known. The document focuses on the United States and states that it will be updated periodically. ( PubMed PMID: 39108079)
Ceftazidime-Avibactam and Imipenem-Relebactam
Ceftazidime-avibactam pairs ceftazidime with avibactam, a non-beta-lactam beta-lactamase inhibitor with a novel mechanism. Unlike tazobactam, avibactam inhibits class A, class C (AmpC), and class D serine beta-lactamases — but critically, does NOT inhibit metallo-beta-lactamases. This means ceftazidime-avibactam is active against AmpC-derepressed Pseudomonas, but not MBL-producers — a similar profile to ceftolozane-tazobactam. When used against isolates without MBLs, ceftazidime-avibactam is often active; it is particularly valuable for GES-type carbapenemase producers that are resistant to ceftolozane-tazobactam.
Imipenem-cilastatin-relebactam adds relebactam, another non-beta-lactam inhibitor, to imipenem-cilastatin. Relebactam inhibits AmpC and class A serine carbapenemases but, again, does not inhibit MBLs. For OprD-restored, AmpC-overexpressing MDR Pseudomonas without MBLs, imipenem-relebactam can restore susceptibility to the imipenem component. The RESTORE-IMI 1 trial was small: 31 patients received imipenem-relebactam and 16 received colistin plus imipenem for imipenem-nonsusceptible pneumonia, abdominal or urinary infections, and P. aeruginosa was the qualifying germ in 77% of the patients analysed. A favourable overall response was seen in 71% versus 70%, a favourable clinical response at day 28 in 71% versus 40%, and death within 28 days in 10% versus 30%. Serious side effects occurred in 10% versus 31%, and kidney damage in 10% versus 56%. ( PubMed PMID: 31400759)
Colistin and Polymyxin B: The Last Resort
Colistin (polymyxin E) and polymyxin B are cationic lipopeptide antibiotics that disrupt the bacterial outer membrane by binding to and displacing divalent cations (calcium and magnesium) that stabilize the lipopolysaccharide layer. This disruption creates pores in the membrane, causing loss of osmotic integrity and bacterial cell death. Against PDR Pseudomonas with no other options, polymyxins are often the only available therapy.
The major limitation of polymyxins is toxicity. Nephrotoxicity occurs in 20 to 50% of patients receiving systemic colistin, including acute kidney injury requiring dialysis. Neurotoxicity (paresthesias, dizziness, neuromuscular blockade) occurs in up to 30%. These toxicities limit dose escalation to achieve optimal pharmacodynamic targets and complicate use in patients with pre-existing renal impairment — who are precisely the critically ill intensive care unit patients most likely to need colistin.
Polymyxin B differs from colistin pharmacokinetically: it is excreted less via the kidney and therefore achieves more predictable plasma concentrations. Some evidence suggests polymyxin B may be associated with less nephrotoxicity than colistin, though direct comparative data are limited. Inhaled colistin is used as an adjunct to systemic therapy in MDR Pseudomonas ventilator-associated pneumonia, achieving very high airway concentrations while minimizing systemic exposure. In a 2014 placebo-controlled trial in intubated intensive care patients, inhaled (aerosolized) antibiotics eradicated 26 of 27 germs present at the start compared with 2 of 23 on placebo, and no new resistance to the inhaled drugs was seen. ( PubMed PMID: 24646034)
Colistin resistance in Pseudomonas is primarily mediated by modifications of the lipid A component of lipopolysaccharide (LPS) that reduce the negative charge, decreasing binding of the cationic polymyxin. The plasmid-mediated mcr resistance genes (common in some Enterobacteriaceae) are rare in Pseudomonas but have been reported. ( PubMed PMID: 17878146)
Bacteriophage Therapy: Viruses That Kill Bacteria
Bacteriophages — viruses that specifically infect and kill bacteria — offer a fundamentally different approach to treating drug-resistant infections. Each phage is highly specific, typically killing only one or a few bacterial strains. This specificity is both a strength (no disruption of normal human microbiome) and a challenge (the right phage must be matched to the patient's strain).
Phage therapy for P. aeruginosa is advancing from laboratory curiosity to clinical reality. Several compelling case reports have documented successful compassionate use treatment of MDR and XDR Pseudomonas infections that failed all antibiotic therapies, including a 2019 report of a 26-year-old woman with cystic fibrosis awaiting a lung transplant whose multidrug-resistant Pseudomonas pneumonia resolved with intravenous phage therapy given alongside antibiotics. The pneumonia had not returned 100 days after phage treatment ended, and she had a successful lung transplant 9 months later. ( PubMed PMID: 31102236)
Key phage therapy concepts:
- Phage cocktails: Combinations of multiple phages with different receptor targets reduce the probability of bacterial resistance to all phages simultaneously.
- Phage-antibiotic synergy: Phages and antibiotics can act synergistically — phages disrupt the biofilm and stress bacterial membranes, improving antibiotic penetration. Some studies show that phage-antibiotic combinations achieve killing of biofilm-embedded bacteria that neither agent achieves alone.
- Anti-biofilm phages: Some phages encode enzymes (depolymerases) that degrade the alginate and polysaccharide matrix of Pseudomonas biofilms, disrupting the biofilm structure and allowing immune cells and antibiotics to access the bacteria within.
- Phage resistance: Bacteria can develop resistance to phages by modifying or losing the surface receptor the phage uses for attachment. Importantly, some phage resistance mutations simultaneously restore antibiotic susceptibility — a phenomenon called "phage-driven antibiotic re-sensitization."
Clinical trials of phage therapy for Pseudomonas are ongoing in cystic fibrosis and ventilator-associated pneumonia settings. ( PubMed PMID: 30651225)
Anti-Quorum Sensing, CRISPR, and Future Directions
Beyond conventional antibiotics and phages, several innovative approaches target P. aeruginosa at different levels of its biology:
Anti-quorum sensing (anti-QS) compounds: Rather than killing bacteria directly (which drives resistance selection), anti-QS compounds disarm the pathogen by silencing its virulence gene networks without affecting growth. Numerous plant-derived compounds (including andrographolide from Andrographis paniculata, ajoene from garlic, and cinnamaldehyde from cinnamon) have demonstrated anti-QS activity in laboratory models. Synthetic anti-QS compounds designed to competitively inhibit LasR — the master QS receptor — are in early development. The anti-virulence approach reduces selective pressure for resistance and may be most useful as adjuncts to antibiotics rather than stand-alone therapies.
CRISPR-Cas-based antimicrobials: CRISPR-Cas systems (clustered regularly interspaced short palindromic repeats, a bacterial gene-cutting defence) can be reprogrammed to target and cut specific sequences of bacterial DNA, destroying the bacterium or selectively eliminating resistance genes. Sequence-specific CRISPR antimicrobials targeting Pseudomonas resistance genes have been demonstrated in laboratory and animal models. Delivery to bacterial cells within biofilms remains a major challenge, with phage-delivered CRISPR systems being explored as a delivery vehicle.
Anti-biofilm enzymes: Dispersin B is an enzyme first found in the gum-disease bacterium Actinobacillus actinomycetemcomitans. It is a sugar-cutting enzyme (a beta-N-acetylglucosaminidase) that splits chains of beta-linked N-acetylglucosamine, and in laboratory experiments it detached cells from established biofilms of that bacterium. ( PubMed PMID: 12896987) Administered with tobramycin, dispersin B dramatically increases tobramycin killing of established Pseudomonas biofilms in animal models.
Immunotherapy: Active and passive immunization targeting Pseudomonas antigens — including alginate, flagella, Psl polysaccharide, and OprF/OprI outer membrane proteins — are being evaluated in clinical trials. Anti-Psl antibody (MEDI3902) combined with anti-PcrV antibody (targeting the Type III secretion system) showed promise in preventing Pseudomonas pneumonia in ventilated patients. Gremubamab is a single bispecific antibody aimed at two Pseudomonas targets at once: the Psl polysaccharide and the PcrV protein of the type III secretion system. In the phase 2 EVADE trial, 188 patients on breathing machines in intensive care whose windpipes carried P. aeruginosa were randomised; Pseudomonas pneumonia occurred in 22.4% of those given the 1,500 mg dose and 18.1% of those given placebo, and the authors concluded that gremubamab did not reduce Pseudomonas pneumonia. ( PubMed PMID: 36380312)
Cefiderocol: Results of the CREDIBLE-CR Trial
Cefiderocol is a newer cephalosporin antibiotic studied in infections caused by carbapenem-resistant Gram-negative bacteria, including P. aeruginosa. In the CREDIBLE-CR trial, 152 hospital patients in 16 countries with serious carbapenem-resistant infections (pneumonia caught in hospital, bloodstream infection or sepsis, or complicated urinary tract infection) were randomly given cefiderocol or the best available therapy chosen in advance by their doctors (up to three drugs).
- Germs involved: among the 118 patients with a confirmed carbapenem-resistant germ, Acinetobacter baumannii caused 46% of infections, Klebsiella pneumoniae 33% and P. aeruginosa 19% (22 patients).
- Cure rates were similar: 50% versus 53% clinical cure in pneumonia, and 43% versus 43% in bloodstream infection or sepsis. In complicated urinary infections the germ was cleared in 53% (9 of 17) versus 20% (1 of 5).
- More deaths on cefiderocol: 34% of patients given cefiderocol and 18% given best available therapy had died by the end of the study, mainly in the group with Acinetobacter infections.
The trial's authors concluded that cefiderocol is an option for carbapenem-resistant infections in patients with limited treatment options. ( PubMed PMID: 33058795)
Key Research Papers
- Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. — PubMed PMID: 29276051
- Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634–640. — PubMed PMID: 11823954
- Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177–192. — PubMed PMID: 30500353
- Meletis G. Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016;3(1):15–21. — PubMed PMID: 26862399
- Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351–1370. — PubMed PMID: 24766095
- Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71(2):304–310. — PubMed PMID: 31545346
- Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439–455. — PubMed PMID: 30270406
- Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007;60(6):1206–1215. — PubMed PMID: 17878146
- Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-18. — PubMed PMID: 30651225
- Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med. 2014;189(10):1225–1233. — PubMed PMID: 24646034
- Sati H, Carrara E, Savoldi A, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. 2025;25(9):1033–1043. — PubMed PMID: 40245910
- Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299–1311. — PubMed PMID: 31563344
- Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024:ciae403. — PubMed PMID: 39108079
- Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799–1808. — PubMed PMID: 31400759
- Law N, Logan C, Yung G, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019;47(4):665–668. — PubMed PMID: 31102236
- Kaplan JB, Ragunath C, Ramasubbu N, Fine DH. Detachment of Actinobacillus actinomycetemcomitans biofilm cells by an endogenous beta-hexosaminidase activity. J Bacteriol. 2003;185(16):4693–4698. — PubMed PMID: 12896987
- Chastre J, François B, Bourgeois M, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022;26(1):355. — PubMed PMID: 36380312
- Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226–240. — PubMed PMID: 33058795